RAS-MAPK in ALK targeted therapy resistance
Authors:
- 2 December 2015
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 14 (23) , 3661-3662
Abstract
The clinical success of ALK targeted therapy is limited by resistance. To identify rational co-targeting strategies to enhance clinical outcomes, we explored the molecular basis of ALK oncogene dependence in ALK gene rearrangement positive (ALK+) lung adenocarcinoma. We discovered that the RAS-RAF-MEK-ERK pathway is the critical downstream pathway necessary for ALK+ tumor cell survival. Upfront co-targeting of ALK plus MEK enhanced response and forestalled resistance in preclinical ALK+ tumor models, providing rationale for a new approach the treatment of ALK+ patients.Keywords
This publication has 6 references indexed in Scilit:
- RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancerNature Medicine, 2015
- Adaptive stress signaling in targeted cancer therapy resistanceOncogene, 2015
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF InhibitorJournal of Clinical Oncology, 2014
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Circumventing Cancer Drug Resistance in the Era of Personalized MedicineCancer Discovery, 2012
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012